- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06746688
Forsøket er et første-i-menneske, fase I, åpent, doseeskalerende forsøk for å vurdere sikkerheten og toleransen til ES2B-C001 kombinert med montanid eller uten montanid, hos pasienter med human epidermal vekstfaktorreseptor 2 (HER2) Uttrykker metastatisk brystkreft
En første-i-menneskelig fase I, åpen, dose-eskalerende studie for å vurdere sikkerhet, tolerabilitet og immunogenisitet/foreløpig antitumoraktivitet av ES2B-C001 med eller uten montanid i HER2-uttrykkende metastatisk brystkreft
The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Graz, Østerrike
- Medical University of Graz
-
Linz, Østerrike, 4010
- Ordensklinikum Linz GmbH Barmherzige Schwestern
-
Vienna, Østerrike, 1090
- Medical University Of Vienna
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients aged ≥18 years at screening visit.
- Diagnosis of HER2-expressing locally advanced, unresectable, or metastatic BC, with HER2 IHC level 1+, 2+ (either FISH negative or positive), or IHC level 3+, after undergoing 2-3 lines of anticancer therapy.
- Life expectancy of at least 3 months.
- ECOG performance status 0-2.
- Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator.
- 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140 ms, or evidence of prior infarction.
- Recovered from side effects, adverse reactions, or adverse events due to prior therapy and/or surgery; any residual toxicities and toxicities related to current anticancer treatment must be ≤ Grade 2, except for alopecia, neuropathy or lymphoedema.
- If female, non-pregnant, postmenopausal, or practicing reliable contraception.
- If male, sterilized or using reliable contraception.
Exclusion Criteria:
- Any planned intravenous chemotherapy regimens or check point inhibitors, or previous therapy with those agents during the past 1 month and the patients are neutropenic. Maintenance therapy with a stable dose of HER2-directed mAbs or treatment with antibody drug conjugates (ADCs) for metastatic BC is allowed at the discretion of the treating physician.
- Symptomatic CNS metastatic disease requiring treatment with high dose steroids (i.e., above 10 mg of prednisone or equivalent) within 14 days prior to first administration of ES2B-C001 (with or without adjuvant).
- Concurrent or recent (within 21 days or 5 half-lives) involvement in any other clinical trial with an investigational drug, device, or other experimental intervention.
- Concomitant severe or uncontrolled underlying medical and/or mental disease unrelated to the tumor, which in the opinion of the investigator is likely to compromise patient safety and affect the trial's outcome.
- Previous documented coronary artery disease or congestive heart failure (>NYHA II).
- Echocardiography with LVEF <50%.
- Uncontrolled hypertension.
- Active, known, or suspected autoimmune disease, except thyroid conditions sufficiently controlled on thyroid hormone therapy, and controlled insulin dependent diabetes.
- Necessity for long-term immunosuppression (≤ 4 mg dexamethasone may be used transiently).
- Systemic infection requiring intravenous antibiotics within 14 days before dosing.
- Chronic use of anti-viral agents, except for human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) treatments.
- History of severe hypersensitivity reactions to any of the trial drug components.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated or recombinant vaccines/killed vaccines are allowed.
- Birthmarks, tattoos, wounds, or skin conditions on deltoid region/buttocks that may obscure the assessment of injection site reactions.
- Female patients who are pregnant, or lactating.
- Any infection (including SARS-CoV-2), that in the opinion of the investigator would, upon inclusion in the trial, lead to potentially harming patients' safety or integrity.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Kohort C1: 50 ug ES2B-C001 med [adjuvans]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
|
Eksperimentell: Kohort C2: 150 ug ES2B-C001 med [adjuvans]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
|
Eksperimentell: Kohort C3: 450µg ES2B-C001 med eller uten [adjuvant]
|
Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations. Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18
|
|
From enrolment to the end of study at week 18
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18
|
Immunogenicity as humoral immune response: Total anti-HER2 Immunoglobulin G (IgG) and IgG lambda titers in sera by enzyme-linked immunosorbent assay (ELISA). |
From enrolment to the end of study at week 18
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18
|
Percentage of patients with measurable disease at baseline achieving Complete Remission (CR) or Partial Response (PR) according to RECIST 1.1 as assessed by the investigator during routine follow up. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18
|
Percentage of patients with Disease Control Rate (DCR) according to RECIST 1.1 as assessed by the investigator during routine follow up. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18
|
Progression free survival (PFS) in patients with Stable Disease (SD), or PR, at the time of first dosing of ES2B-C001 alone or in combination with [adjuvant] according to RECIST 1.1. |
From enrolment to the end of study at week 18
|
|
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18
|
Overall survival (OS) |
From enrolment to the end of study at week 18
|
|
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18
|
Optionally, other immunogenicity and biomarker readouts: characterization of anti-HER2 immunoglobulins in selected sera, including isotyping (e.g. IgM, IgG and IgG subclasses IgG1-4, IgD, IgE, IgA); analysis of HER2 epitope recognition profiles; cellular immune responses; in vitro cell stimulation assays; and measuring circulating tumor DNA. |
From enrolment to the end of study at week 18
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Thomas K. Jorgensen, ExpreS2ion Biotechnologies
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ES2B-C001-S01
- 2024-516333-12-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Within the study de-identified patient data will be shared with
- the operational study team, sponsor, auditor and for reporting of safety events to the regulatory agencies and EC
- Data Monitoring Committees/ or other independent committees during the study
- At the end - data listings are part of the Appendices of the CSR which will be shared to regulatory agencies and EC
IPD-deling Støtteinformasjonstype
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .